Wuxi Biologics (Cayman) ( (HK:2269) ) has issued an update.
Wuxi Biologics has announced the approval of a grant of 25,520,857 restricted shares under its Restricted Share Award Scheme, aimed at motivating employees and aligning their interests with the company’s growth. The shares will vest over a period of five years, with a clawback mechanism in place for certain conditions, ensuring the scheme supports long-term engagement and performance.
More about Wuxi Biologics (Cayman)
Wuxi Biologics (Cayman) Inc. operates in the biotechnology industry, focusing on providing biologics discovery, development, and manufacturing services. The company is known for its comprehensive and integrated services that cater to the needs of the pharmaceutical and healthcare sectors.
YTD Price Performance: 71.30%
Average Trading Volume: 3,786
Technical Sentiment Signal: Sell
Current Market Cap: $13.68B
See more insights into 2269 stock on TipRanks’ Stock Analysis page.